EU GDPEU Good Distribution Practice (2013/C 343/01)

EU GDP (Guidelines 2013/C 343/01, replacing the earlier 94/C 63/03 guidelines) is the binding standard for wholesale distribution of medicinal products for human use across the EU/EEA. It applies to any entity that procures, holds, supplies or exports medicines other than to the public — manufacturers' own distribution, pharmaceutical wholesalers, parallel importers, 3PLs handling pharmaceuticals, and brokers (who never take physical possession but must still hold a registration and operate a quality system). Veterinary GDP and active-substance GDP are separate documents (2015/C 95/01 for APIs).

1. Chapter 1 — Quality management (PQS, change control, deviation, CAPA, MARS).
2. Chapter 2 — Personnel (Responsible Person, training, hygiene).
3. Chapter 3 — Premises and equipment (temperature/humidity control, segregation, mapping, security).
4. Chapter 4 — Documentation (procedures, records, retention).
5. Chapter 5 — Operations (qualification of suppliers and customers, receipt, storage, picking, supply, export).
6. Chapter 6 — Complaints, returns, suspected falsified medicines, recalls.
7. Chapter 7 — Outsourced activities (contract giver / acceptor, written agreement).
8. Chapter 8 — Self-inspections.
9. Chapter 9 — Transportation (temperature control en route, vehicle qualification, third-party carriers).
10. Chapter 10 — Specific provisions for brokers.

Every Wholesale Distribution Authorisation (WDA) holder must designate at least one Responsible Person who is contactable, appropriately qualified (typically a pharmacist or equivalent in the UK / Ireland / NL; varies by Member State) and who personally takes responsibility for the quality system, the staff training, the temperature-mapping programme, the customer/supplier qualification, the recall procedure and the relationship with the competent authority. The RP's name and qualifications appear on the WDA. A change of RP is a variation that must be notified within 30 days. MHRA and other competent authorities have suspended WDAs where the RP was 'in name only' and not actually exercising oversight.

GDP §3.2 requires storage areas to be qualified by temperature mapping under representative load conditions, covering the worst-case zones (corners, near doors, near lighting/HVAC). The mapping demonstrates the area holds the labelled storage condition (2-8 °C, ≤25 °C, ≤30 °C as the SmPC dictates) and identifies positioning of continuous monitors. Mapping is repeated at defined intervals and on major changes (re-arrangement, HVAC change, season — many sites do summer + winter mapping).

GDP §9.4 extends the same logic to transport: the route must be qualified to deliver the labelled condition through the worst-case season, the vehicle/container is qualified once and route-monitored every shipment for cold-chain products (≤8 °C). Excursions are documented, root-caused and the impact on product is assessed before further distribution.

GDP §5.2 requires the wholesaler to verify every supplier — manufacturers must hold a Manufacturing Authorisation, wholesalers a WDA; the WDA must be checked on the EudraGMDP database before the first transaction and on a periodic basis. Customers (§5.3) must be authorised to receive medicines — pharmacy, hospital, another wholesaler, or licensed entity. Supply to an unauthorised entity is a Critical finding and a criminal offence in most Member States.

Falsified Medicines Directive (FMD, 2011/62/EU) operationalised by Delegated Regulation 2016/161 requires every prescription pack (with very narrow whitelist exceptions) to carry a unique identifier (2D Data Matrix) and a tamper-evident seal. Wholesalers must verify the UID through the European Medicines Verification System (EMVS) at defined risk points — return-to-saleable-stock, supply to entities other than pharmacies, and decommissioning before export to non-EU markets. GDP Chapter 6 also requires the wholesaler to quarantine and report any suspected falsified medicine immediately.

• Returns can only be returned to saleable stock if temperature, container-closure integrity and FMD safety features are intact — the RP signs off.
• Recalls must be initiated within stated timeframes (Class I typically 24-48 hours in most Member States); the wholesaler must be able to identify and reach every onward consignee.
• Complaints are categorised (product quality, suspected falsified, distribution error) and routed to the manufacturer for product-quality complaints; an internal CAPA addresses any wholesaler-side cause.

Whether the wholesaler uses its own fleet or a third-party carrier, GDP holds the WDA holder responsible for the conditions during transport. Third-party agreements must be in place; carriers must be assessed (a written quality questionnaire at minimum; routine audits for cold-chain or high-value lanes). Active and passive temperature-controlled containers are qualified per ISTA 7E or equivalent; route-specific risk assessment drives whether dry-ice top-ups, gel packs or active reefer is appropriate. Cold-chain shipments require continuous monitoring with a temperature log retrievable per shipment.

1. Temperature mapping out of date or done under non-representative loading.
2. RP not exercising effective oversight (no documented walk-throughs, no review of CAPA register).
3. Supplier WDA not verified on EudraGMDP before purchase.
4. Return-to-saleable-stock without documented temperature evidence.
5. Excursion not investigated for product impact, just acknowledged.
6. Third-party carrier with no Quality Agreement.
7. FMD verification not happening at the §23 / §24 risk points.
8. Self-inspection programme either absent or treated as a tick-box.

• WDA-holder workspace: holds the RP, the deputies, every supplier WDA / MIA reference (linked to EudraGMDP), every customer authorisation reference, and the periodic-verification schedule.
• Temperature monitoring: every storage area + every vehicle + every passive shipper carries continuous probes; data lands on the lot's distribution record. Mapping reports + alarms with alert + action levels (alert inside the spec, action at the spec edge); excursion auto-opens a deviation with mandatory product-impact assessment before stock is released.
• FMD verification: scan-in at receipt, scan-out at supply, decommission at export — every transaction logged with the UID, the EMVS response and the timestamp; quarantine triggers immediately on a NOT-FOUND or ALREADY-DECOMMISSIONED response.
• Returns flow: the return cannot be set to saleable until temperature continuity, tamper seal and FMD safety feature are verified; RP e-signature closes the loop.
• Recall execution: by lot, by UID range or by SSCC; the system identifies every onward consignee in seconds, generates the recall letter, tracks acknowledgement and quarantines on-hand stock.
• Self-inspection programme: scheduled, evidenced, findings tracked to CAPA — and visible to the RP on one dashboard.